Concordance with NCCN treatment guidelines: Relations with health care utilization, cost, and mortality in breast cancer patients with secondary metastasis

The impact of National Comprehensive Cancer Network (NCCN) treatment guideline concordance on costs, health care utilization, and mortality for patients with breast cancer and secondary metastases is unknown.

[1]  L. Newcomer,et al.  Payer View of High-Quality Clinical Pathways for Cancer. , 2017, Journal of oncology practice.

[2]  C. Nabhan,et al.  Oncology Pathways-Preventing a Good Idea From Going Bad. , 2016, JAMA oncology.

[3]  A. Trentham-Dietz,et al.  Influence of patient, physician, and hospital characteristics on the receipt of guideline-concordant care for inflammatory breast cancer. , 2016, Cancer epidemiology.

[4]  L. Bosserman,et al.  American Society of Clinical Oncology Policy Statement on Clinical Pathways in Oncology. , 2016, Journal of oncology practice.

[5]  Benjamin O. Anderson,et al.  Breast cancer version 2.2015: Clinical practice guidelines in oncology , 2015 .

[6]  M. Piccart,et al.  ESO-ESMO 2nd international consensus guidelines for advanced breast cancer (ABC2)† , 2014, Annals of oncology : official journal of the European Society for Medical Oncology.

[7]  A. Abernethy,et al.  Delivering high-quality and affordable care throughout the cancer care continuum. , 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[8]  M. Blettner,et al.  Adherence to treatment guidelines and survival in triple-negative breast cancer: a retrospective multi-center cohort study with 9156 patients , 2013, BMC Cancer.

[9]  E. Kreys,et al.  Documenting the benefits and cost savings of a large multistate cancer pathway program from a payer's perspective. , 2013, Journal of oncology practice.

[10]  Richard L Schilsky,et al.  Prevalence of off-label use and spending in 2010 among patent-protected chemotherapies in a population-based cohort of medical oncologists. , 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[11]  J. Baselga,et al.  Trastuzumab emtansine for HER2-positive advanced breast cancer. , 2012, The New England journal of medicine.

[12]  C. Hudis,et al.  1st International consensus guidelines for advanced breast cancer (ABC 1). , 2012, Breast.

[13]  B. Feinberg,et al.  Implementation of cancer clinical care pathways: a successful model of collaboration between payers and providers. , 2012, Journal of oncology practice.

[14]  K. Lindquist,et al.  Effect of Central Nervous System Metastases on Treatment Discontinuation and Survival in Older Women Receiving Trastuzumab for Metastatic Breast Cancer , 2012, Journal of cancer epidemiology.

[15]  C. Vogel,et al.  Bevacizumab in the Treatment of Metastatic Breast Cancer: Friend or Foe? , 2012, Current Oncology Reports.

[16]  D. Patt,et al.  Pathways, outcomes, and costs in colon cancer: retrospective evaluations in 2 distinct databases. , 2011, The American journal of managed care.

[17]  R. Kreienberg,et al.  Effects of guideline adherence in primary breast cancer--a 5-year multi-center cohort study of 3976 patients. , 2010, Breast.

[18]  C. Compton,et al.  The American Joint Committee on Cancer: the 7th Edition of the AJCC Cancer Staging Manual and the Future of TNM , 2010, Annals of Surgical Oncology.

[19]  D W Hillman,et al.  North Central Cancer Treatment Group (NCCTG) N0432: phase II trial of docetaxel with capecitabine and bevacizumab as first-line chemotherapy for patients with metastatic breast cancer. , 2010, Annals of oncology : official journal of the European Society for Medical Oncology.

[20]  Katherine S Panageas,et al.  A Phase II Trial of Erlotinib in Combination with Bevacizumab in Patients with Metastatic Breast Cancer , 2008, Clinical Cancer Research.

[21]  E. Perez,et al.  Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer. , 2007, The New England journal of medicine.

[22]  B. Ramaswamy,et al.  Phase II Trial of Bevacizumab in Combination with Weekly Docetaxel in Metastatic Breast Cancer Patients , 2006, Clinical Cancer Research.

[23]  M. Stokes,et al.  Ten-year survival and cost following breast cancer recurrence: estimates from SEER-medicare data. , 2005, Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research.

[24]  L. Harris,et al.  First-Line Herceptin® Monotherapy in Metastatic Breast Cancer , 2001, Oncology.

[25]  B. Hillner,et al.  Ensuring quality cancer care by the use of clinical practice guidelines and critical pathways. , 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[26]  J L Warren,et al.  Development of a comorbidity index using physician claims data. , 2000, Journal of clinical epidemiology.

[27]  R. Deyo,et al.  Adapting a clinical comorbidity index for use with ICD-9-CM administrative databases. , 1992, Journal of clinical epidemiology.

[28]  C. Sima,et al.  Prevalence and Safety of Off-Label Use of Chemotherapeutic Agents in Older Patients With Breast Cancer: Estimates From SEER-Medicare Data. , 2016, Journal of the National Comprehensive Cancer Network : JNCCN.

[29]  Eld,et al.  ESO-ESMO 2nd international consensus guidelines for advanced breast cancer (ABC2) , 2014, Breast.

[30]  L. V. van't Veer,et al.  ESO-ESMO 2nd international consensus guidelines for advanced breast cancer (ABC2). , 2014, Breast.

[31]  Lonny Reisman,et al.  Cost effectiveness of evidence-based treatment guidelines for the treatment of non-small-cell lung cancer in the community setting. , 2010, Journal of oncology practice.

[32]  J. Warren,et al.  Overview of the SEER—Medicare Health Outcomes Survey Linked Dataset , 2008, Health care financing review.

[33]  C. Mackenzie,et al.  A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. , 1987, Journal of chronic diseases.